Immune-Onc Therapeutics
Latest round
- Series B
Last raised
- Jan 2023
Total raised
- $138M
Investors
- 11
About Immune-Onc Therapeutics
Based in California, US, and founded in 2016, Immune-Onc Therapeutics, Inc. operates as a clinical-stage cancer immunotherapy company. The company was founded by Charlene Liao. In March 2021, Immune-Onc Therapeutics, Inc. Immune-Onc Therapeutics, Inc. is a developer of immunotherapies approaches such as Leukocyte Immunoglobulin-like Receptor subfamily B (LILRB), LAIR1, IO-202, IO-106, and IO-108. Immune-Onc Therapeutics, Inc.
Who invested in Immune-Onc Therapeutics
11 investors across 4 rounds
See all investors in Immune-Onc Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immune-Onc Therapeutics
Who invested in Immune-Onc Therapeutics?
Immune-Onc Therapeutics has 11 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immune-Onc Therapeutics raised?
Immune-Onc Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Immune-Onc Therapeutics last raise money?
Immune-Onc Therapeutics's most recent round on record is a Series B, in Jan 2023.
What does Immune-Onc Therapeutics do?
Based in California, US, and founded in 2016, Immune-Onc Therapeutics, Inc.
Where is Immune-Onc Therapeutics headquartered?
Immune-Onc Therapeutics is headquartered in Palo Alto, US.
Which VCs invest in companies like Immune-Onc Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Immune-Onc Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Immune-Onc Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.